1. Home
  2. MBX vs GNE Comparison

MBX vs GNE Comparison

Compare MBX & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBX
  • GNE
  • Stock Information
  • Founded
  • MBX 2018
  • GNE 2011
  • Country
  • MBX United States
  • GNE United States
  • Employees
  • MBX N/A
  • GNE N/A
  • Industry
  • MBX
  • GNE Power Generation
  • Sector
  • MBX
  • GNE Utilities
  • Exchange
  • MBX NYSE
  • GNE Nasdaq
  • Market Cap
  • MBX 347.9M
  • GNE 402.8M
  • IPO Year
  • MBX 2024
  • GNE N/A
  • Fundamental
  • Price
  • MBX $6.97
  • GNE $15.27
  • Analyst Decision
  • MBX Strong Buy
  • GNE
  • Analyst Count
  • MBX 4
  • GNE 0
  • Target Price
  • MBX $37.25
  • GNE N/A
  • AVG Volume (30 Days)
  • MBX 223.9K
  • GNE 72.2K
  • Earning Date
  • MBX 03-17-2025
  • GNE 03-10-2025
  • Dividend Yield
  • MBX N/A
  • GNE 1.96%
  • EPS Growth
  • MBX N/A
  • GNE N/A
  • EPS
  • MBX N/A
  • GNE 0.46
  • Revenue
  • MBX N/A
  • GNE $425,202,000.00
  • Revenue This Year
  • MBX N/A
  • GNE N/A
  • Revenue Next Year
  • MBX N/A
  • GNE N/A
  • P/E Ratio
  • MBX N/A
  • GNE $27.77
  • Revenue Growth
  • MBX N/A
  • GNE N/A
  • 52 Week Low
  • MBX $6.67
  • GNE $13.05
  • 52 Week High
  • MBX $27.50
  • GNE $17.93
  • Technical
  • Relative Strength Index (RSI)
  • MBX N/A
  • GNE 56.46
  • Support Level
  • MBX N/A
  • GNE $14.79
  • Resistance Level
  • MBX N/A
  • GNE $15.94
  • Average True Range (ATR)
  • MBX 0.00
  • GNE 0.52
  • MACD
  • MBX 0.00
  • GNE 0.09
  • Stochastic Oscillator
  • MBX 0.00
  • GNE 66.67

About MBX MBX BIOSCIENCES INC

MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

About GNE Genie Energy Ltd. Class B Stock

Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.

Share on Social Networks: